<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00280878</url>
  </required_header>
  <id_info>
    <org_study_id>AH204/05</org_study_id>
    <nct_id>NCT00280878</nct_id>
  </id_info>
  <brief_title>Rituximab in Combination With Outpatient Therapy for CD20+ Lymphoma</brief_title>
  <official_title>A Pilot Study of Rituximab in Combination With Out-patient Based VGF/F-GIV Salvage Therapies for Relapsed/Refractory CD20+ Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayside Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayside Health</source>
  <brief_summary>
    <textblock>
      This is a Phase II pilot study evaluating the safety of a risk-adjusted outpatient-based&#xD;
      approach to lymphoma salvage therapy with VGF (vinorelbine, gemcitabine and pegfilgrastim)&#xD;
      and/or F-GIV (gemcitabine, Ifosfamide, vinorelbine and pegfilgrastim) in combination with&#xD;
      Rituximab (R-VGF/R-F-GIV).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recent epidemiologic surveys have demonstrated a dramatic increase in the incidence of&#xD;
      non-Hodgkin's lymphoma (NHL). NHL is now one of the most rapidly increasing malignancies in&#xD;
      the industrial world.&#xD;
&#xD;
      The purpose of this project is to evaluate the efficacy and safety of an outpatient treatment&#xD;
      for relapsed or treatment resistant (refractory) CD20+ lymphoma. Two combinations of&#xD;
      chemotherapy drugs will be tested depending on the patients prior therapy and response -&#xD;
      rituximab, vinorelbine and gemcitabine (R-VGF) OR rituximab, vinorelbine, gemcitabine and&#xD;
      ifosfamide (R-FGIV).&#xD;
&#xD;
      Previous experience, including a recently completed study using combinations of vinorelbine,&#xD;
      gemcitabine and ifosfamide has demonstrated that such an outpatient approach is safe and of&#xD;
      similar efficacy to presently available alternative inpatient chemotherapy approaches. This&#xD;
      study is expanding on the findings from the previous study by adding rituximab.&#xD;
&#xD;
      Rituximab is being increasingly and successfully used in the therapy of CD20+ NHL. It is a&#xD;
      specific protein (antibody) that is directed against the surface protein (CD20 antigen) found&#xD;
      on CD20+ lymphoma cells and can therefore lead to the destruction of these cells. Rituximab&#xD;
      also has a highly favourable toxicity profile enabling outpatient treatment.&#xD;
&#xD;
      All of these factors provide a strong rationale for the combination of rituximab and the&#xD;
      novel outpatient-based salvage approaches VGF and F-GIV that we have recently evaluated. This&#xD;
      pilot study of 12 patients will test the feasibility of this combination approach in patients&#xD;
      with relapsed/refractory CD20+ NHL.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety of a risk-adjusted outpatient-based approach to lymphoma salvage therapy with VGF and/or F-GIV in combination with Rituximab.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine point estimates of the response rates achieved with R-VGF or R-F-GIV in previously treated patients with relapsed/refractory CD20+ B-cell NHL.</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Non-Hodgkin's Lymphoma (CD20+)</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinorelbine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ifosfamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rituximab</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;18 years&#xD;
&#xD;
          -  Relapsed or primary refractory CD20+ NHL&#xD;
&#xD;
          -  ECOG 0 - 2&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Intention to proceed with any form of transplant therapy following fewer than 2 cycles&#xD;
             of protocol salvage therapy.&#xD;
&#xD;
          -  Bilirubin &gt; 50Âµmol/litre unless secondary to lymphoma&#xD;
&#xD;
          -  Creatinine &gt; 2 x upper limit of normal unless secondary to lymphoma&#xD;
&#xD;
          -  Absolute neutrophil count &lt;0.5 x 109/litre and / or platelets &lt; 50 x 109/litre unless&#xD;
             secondary to lymphoma&#xD;
&#xD;
          -  Relapse within 6 months of a prior transplant procedure (autologous or allogeneic).&#xD;
&#xD;
          -  Known sensitivity to E coli derived preparations&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Spencer, Assoc.Prof</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frankston Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>October 2007</verification_date>
  <study_first_submitted>January 22, 2006</study_first_submitted>
  <study_first_submitted_qc>January 22, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2006</study_first_posted>
  <last_update_submitted>January 13, 2016</last_update_submitted>
  <last_update_submitted_qc>January 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lymphoma</keyword>
  <keyword>CD20+</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

